To create an interactive web-based tool for the Prediction of Risk of Metastasis in Uveal Melanoma (PRiMeUM) that can provide a personalized risk estimate of developing metastases within 48 months of primary uveal melanoma (UM) treatment.,The model utilizes routinely collected clinical and tumor characteristics on 1227 UM, with the option of including chromosome information when available.,Using a cohort of 1227 UM cases, Cox proportional hazard modeling was used to assess significant predictors of metastasis including clinical and chromosomal characteristics.,A multivariate model to predict risk of metastasis was evaluated using machine learning methods including logistic regression, decision trees, survival random forest, and survival-based regression models.,Based on cross-validation results, a logistic regression classifier was developed to compute an individualized risk of metastasis based on clinical and chromosomal information.,The PRiMeUM model provides prognostic information for personalized risk of metastasis in UM.,The accuracy of the risk prediction ranged between 80% (using chromosomal features only), 83% using clinical features only (age, sex, tumor location, and size), and 85% (clinical and chromosomal information).,Kaplan-Meier analysis showed these risk scores to be highly predictive of metastasis (P < 0.0001).,PRiMeUM provides a tool for predicting an individual's personal risk of metastasis based on their individual and tumor characteristics.,It will aid physicians with decisions concerning frequency of systemic surveillance and can be used as a criterion for entering clinical trials for adjuvant therapies.
To detect and quantify circulating tumour cells (CTCs) in peripheral blood of patients with uveal melanoma primary non-metastatic tumours, and to analyze the possible relationship between CTCs and clinical risk factors.,Prospective study with two clinical groups: 4 patients diagnosed with choroidal nevus and 8 patients with choroidal melanoma prior to treatment.,A single sample of 7.5 mL of peripheral blood was taken and the CTCs were isolated using a CellSearch system that captures positive cells for the CD146 antigen (MUC18).,None of the patients with choroidal nevus showed CTCs in peripheral blood.,More than one CTC/7.5 mL was detected in 50 % of patients with choroidal melanoma prior to treatment.,The higher level of CTC cells in peripheral blood (3/7.5 mL) was detected in the patient with the larger choroidal melanoma which also presented extrascleral extension and epithelioid pathology.,Performing an analysis with the CellSearch system allows to quantify the choroidal melanoma CTCs in peripheral blood.,This finding highlights the potential usefulness of this technique to achieve the correct stratification and monitoring of the treatment.